A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products
NCT ID: NCT03037359
Last Updated: 2023-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2016-12-31
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)
NCT00538915
Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients
NCT00138697
Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)
NCT00322556
Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%
NCT02269163
Efficacy and Safety and Pharmacokinetics of Boya IVIG
NCT06150833
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bivigam
Patients with primary immunodeficiency disease treated with Bivigam™
Bivigam
Human immune globulin
Other IGIV
Patients with primary immunodeficiency disease treated with other IGIVs
Other
Human immune globulin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bivigam
Human immune globulin
Other
Human immune globulin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Current subjects requiring treatment with an IGIV
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ADMA Biologics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Santa Barbara Specialty Pharmacy
Carpinteria, California, United States
Allergy and Asthma of the Bay Area
Walnut Creek, California, United States
Immunoe Research Centers
Centennial, Colorado, United States
Central Georgia Infectious Disease Consultants
Macon, Georgia, United States
Midwest Allergy and Sinus
Normal, Illinois, United States
Kanarek Adult & Pediatric Allergy & Immunology
Overland Park, Kansas, United States
Infectious Disease Consultants
Wichita, Kansas, United States
The Center for Allergy, Asthma & Immunology
Syosset, New York, United States
Allergy Asthma & Immunology Relief
Charlotte, North Carolina, United States
Ohio Clinical Research Associates
Mayfield Heights, Ohio, United States
Oklahoma Institute of Allergy and Asthma Clinical Research
Oklahoma City, Oklahoma, United States
Austin Infectious Disease Consultants
Austin, Texas, United States
Discovery Clinical Trials
Dallas, Texas, United States
Allergy Partners of North Texas
Dallas, Texas, United States
Allergy Immunology and Respiratory Care
Dallas, Texas, United States
University of Texas Southwestern Medical Center
Irving, Texas, United States
Lysosomal Rare Disorders Research & Treatment Center
Fairfax, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
017
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.